Clinical Trial Update: The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

View source ↗

Summary

A completed clinical trial reports that using 5% intravenous immunoglobulin reduces adverse events for patients with primary immunodeficiency who experience rea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• Intravenous Immunoglobulin (5%) (intravenous immunoglobulin)
• Intravenous immunoglobulin 10% (intravenous immunoglobulin)

Snippet

Sponsor: IMMUNOe Research Centers | Conditions: Primary Immunodeficiency | Status: COMPLETED